# US 2026/0083734 A1 · Dosage forms for tyk2 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083734 A1
- Document ID: US20260083734A1
- Status: Published application
- Kind: A1
- Application number: 19/406,929
- Filed: 2025-12-02
- Published: 2026-03-26
- Earliest claimed: 2019-09-18
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Sherif Ibrahim Farag Badawy; Jonathan R. Brown; Candice Y. Choi; Christoph Gesenberg; Vivienne Gray; John Wynne Jones; Umesh Kestur; Balvinder S. Vig; Xiaotian S. Yin; Christopher A. Zordan; Corey Bloom; Ian Yates
- Web page: https://patentgrep.com/patent/US20260083734A1

## CPC

- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/1694: {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/284: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I); BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis:

## Claims

### Claim 1

A dosage form of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (BMS-986165), the dosage form comprising a dispersion of amorphous BMS-986165 dispersed in a polymer matrix;
wherein the proportion of amorphous BMS-986165 to polymer in the dispersion is 3%-80% w/w amorphous BMS-986165 to 97%-20% w/w polymer; and
wherein the polymer in the polymer matrix comprises one or more of:
hydroxypropyl methylcellulose (HPMC), hypromellose phthalate (HPMC-P), hydroxypropyl methylcellulose acetate succinate (HPMCAS), and Eudragit L100-55.

### Claim 2 (depends on 1)

The dosage form according to claim 1, wherein the dispersion comprises the amorphous BMS-986165 in an amount that is no greater than 25% w/w of the dispersion.

### Claim 3 (depends on 1)

The dosage form according to claim 1, wherein the polymer in the polymer matrix comprises one or more of: hydroxypropyl methylcellulose (HPMC), hypromellose phthalate (HPMC-P), and hydroxypropyl methylcellulose acetate succinate (HPMCAS).

### Claim 4 (depends on 2)

The dosage form according to claim 2, wherein the polymer in the polymer matrix comprises one or more of: hydroxypropyl methylcellulose (HPMC), hypromellose phthalate (HPMC-P), and hydroxypropyl methylcellulose acetate succinate (HPMCAS).

### Claim 5 (depends on 4)

The dosage form according to claim 4, wherein the polymer in the polymer matrix comprises hydroxypropyl methylcellulose (HPMC).

### Claim 6 (depends on 1)

The dosage form according to claim 1, wherein the BMS-986165 in the dosage form exhibits less than 5% degradation following storage of the dosage form at 40° C./75% Relative Humidity for at least one month.

### Claim 7 (depends on 1)

The dosage form according to claim 1, wherein the BMS 986165 in the dosage form exhibits less than 10% crystallization following storage of the dosage form at 40° C./75% Relative Humidity for at least one month.

### Claim 8 (depends on 1)

The dosage form according to claim 1, wherein at least 80% of the BMS-986165 in the dosage form is released by 60 minutes after the dosage form is placed in a medium simulating the fasted stomach.

### Claim 9 (depends on 1)

The dosage form according to claim 1, wherein at least 80% of the BMS-986165 in the dosage form is released by 30 minutes after the dosage form is placed in a medium having a pH from 1 to 2.

### Claim 10 (depends on 1)

The dosage from according to claim 1, wherein at least 80% of the BMS-986165 in the dosage form is released by 30 minutes after the dosage form is placed in a medium having a pH from 6 to 7.

### Claim 11 (depends on 1)

The dosage form according to claim 1, wherein the dosage form is an oral dosage form, and bioavailability of BMS-986165 from the oral dosage form is measured by area under the curve of a plasma-concentration-versus-time curve,
wherein the bioavailability of BMS-986165 from the oral dosage form administered to a subject concurrently with a gastric pH-raising agent differs by no more than 25% from the bioavailability of BMS-986165 from the oral dosage form administered to the subject without concurrent administration of the gastric pH-raising agent.

### Claim 12 (depends on 11)

The dosage form according to claim 11, wherein the gastric pH-raising agent is a proton pump inhibitor, an antacid, or an H2 receptor antagonist.

### Claim 13

A dosage form of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (BMS-986165), the dosage form comprising a dispersion of amorphous BMS-986165 dispersed in a polymer matrix;
wherein the polymer matrix comprises one or more of: hydroxypropyl methylcellulose (HPMC), hypromellose phthalate (HPMC-P), and hydroxypropyl methylcellulose acetate succinate (HPMCAS); and
wherein the BMS-986165 in the dosage form exhibits less than 5% degradation following storage of the dosage form at 40° C./75% Relative Humidity for at least one month.

### Claim 14 (depends on 13)

The dosage form according to claim 13, wherein the dispersion comprises the amorphous BMS-986165 in an amount that is no greater than 25% w/w of the dispersion.

### Claim 15 (depends on 14)

The dosage form according to claim 14, wherein the polymer in the polymer matrix comprises HPMC, and wherein the HPMC is HPMC E3.

### Claim 16

A dosage form of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (BMS-986165), the dosage form comprising a dispersion of amorphous BMS-986165 dispersed in a polymer matrix;
wherein the polymer matrix comprises one or more of: hydroxypropyl methylcellulose (HPMC), hypromellose phthalate (HPMC-P), hydroxypropyl methylcellulose acetate succinate (HPMCAS), and Eudragit L100-55; and
wherein the BMS 986165 in the dosage form exhibits less than 10% crystallization following storage of the dosage form at 40° C./75% Relative Humidity for at least one month.

### Claim 17 (depends on 16)

The dosage form according to claim 16, wherein the dispersion comprises the amorphous BMS-986165 in an amount that is no greater than 25% w/w of the dispersion.

### Claim 18 (depends on 16)

The dosage form according to claim 16, wherein the polymer in the polymer matrix comprises one or more of: hydroxypropyl methylcellulose (HPMC), hypromellose phthalate (HPMC-P), and hydroxypropyl methylcellulose acetate succinate (HPMCAS).

### Claim 19 (depends on 17)

The dosage form according to claim 17, wherein the dispersion comprises the amorphous BMS-986165 in an amount that is at least 10% w/w of the dispersion.

### Claim 20

A dosage form of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (BMS-986165), the dosage form comprising a dispersion of amorphous BMS-986165 dispersed in a polymer matrix;
wherein the polymer matrix comprises one or more of: hydroxypropyl methylcellulose (HPMC), hypromellose phthalate (HPMC-P), and hydroxypropyl methylcellulose acetate succinate (HPMCAS); and
wherein the BMS 986165 in the dosage form exhibits less than 5% crystallization following storage of the dosage form at 40° C./75% Relative Humidity for at least one month.

### Claim 21 (depends on 20)

The dosage form according to claim 20, wherein the dispersion comprises the amorphous BMS-986165 in an amount that is no greater than 25% w/w of the dispersion.

### Claim 22 (depends on 16)

The dosage form according to claim 16, wherein the BMS-986165 in the dosage form exhibits less than 5% degradation following storage of the dosage form at 40° C./75% Relative Humidity for at least one month.

### Claim 23 (depends on 20)

The dosage form according to claim 20, wherein the BMS-986165 in the dosage form exhibits less than 5% degradation following storage of the dosage form at 40° C./75% Relative Humidity for at least one month.

### Claim 24 (depends on 1)

A method of treating one or more of psoriasis and psoriatic arthritis in a human subject, the method comprising administering to the human subject the dosage form according to claim 1.

### Claim 25 (depends on 13)

A method of treating one or more of psoriasis and psoriatic arthritis in a human subject, the method comprising administering to the human subject the dosage form according to claim 13.

### Claim 26 (depends on 16)

A method of treating one or more of psoriasis and psoriatic arthritis in a human subject, the method comprising administering to the human subject the dosage form according to claim 16.

### Claim 27 (depends on 20)

A method of treating one or more of psoriasis and psoriatic arthritis in a human subject, the method comprising administering to the human subject the dosage form according to claim 20.

### Claim 28 (depends on 21)

A method of treating one or more of psoriasis and psoriatic arthritis in a human subject, the method comprising administering to the human subject the dosage form according to claim 21.

### Claim 29 (depends on 24)

The method according to claim 24, wherein the amount of BMS-986165 in the dosage form is 6 mg.

### Claim 30 (depends on 27)

The method according to claim 27, wherein the amount of BMS-986165 in the dosage form is 6 mg.
